Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity
PT Kennedy, EL Saulters, AD Duckworth, YJ Lim… - Molecular Therapy, 2024 - cell.com
CTLA-4 is a crucial immune checkpoint receptor involved in the maintenance of immune
homeostasis, tolerance, and tumor control. Antibodies targeting CTLA-4 have been …
homeostasis, tolerance, and tumor control. Antibodies targeting CTLA-4 have been …
PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy
JM DeRogatis, KM Viramontes, EN Neubert… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the
treatment of many cancer types and are now standard therapies for patients. While standard …
treatment of many cancer types and are now standard therapies for patients. While standard …
The immune microenviroment in somatotropinomas: from biology to personalized and target therapy
S Chiloiro, L De Marinis - Reviews in Endocrine and Metabolic Disorders, 2023 - Springer
Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior,
due to their clinical course, local invasive growth, resistance to conventional therapies and …
due to their clinical course, local invasive growth, resistance to conventional therapies and …
The molecular and microenvironmental landscape of glioblastomas: Implications for the novel treatment choices
F Di Cintio, M Dal Bo, L Baboci, E De Mattia… - Frontiers in …, 2020 - frontiersin.org
Glioblastoma (GBM) is the most frequent and aggressive primary central nervous system
tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents …
tumor. Surgery followed by radiotherapy and chemotherapy with alkylating agents …
Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade
F Santinon, BF Ezzahra, M Bachais, A Sarabia Pacis… - Scientific Reports, 2022 - nature.com
PD-1 immune checkpoint blockade against inhibitory receptors such as receptor
programmed cell death-1 (PD-1), has revolutionized cancer treatment. Effective immune …
programmed cell death-1 (PD-1), has revolutionized cancer treatment. Effective immune …
[HTML][HTML] Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold'tumors
M Semmrich, JB Marchand, L Fend… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) is a clinically proven concept to treat
cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated …
cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated …
Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
KM Hargadon - Clinical and Translational Medicine, 2020 - Wiley Online Library
Cancer immunotherapy is fast becoming one of the most promising means of treating
malignant disease. Cancer vaccines, adoptive cell transfer therapies, and immune …
malignant disease. Cancer vaccines, adoptive cell transfer therapies, and immune …
Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer
PF Brunsvig, TK Guren, M Nyakas… - Frontiers in …, 2020 - frontiersin.org
Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer
immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a …
immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a …
Immune checkpoint-related gene polymorphisms are associated with primary immune thrombocytopenia
S Wang, X Zhang, S Leng, Q Xu, Z Sheng… - Frontiers in …, 2021 - frontiersin.org
Cancer immunotherapy by immune checkpoint blockade has been effective in the treatment
of certain tumors. However, the association between immune checkpoints and autoimmune …
of certain tumors. However, the association between immune checkpoints and autoimmune …
[HTML][HTML] The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
AM Di Giacomo, M Lahn, AMM Eggermont… - European Journal of …, 2023 - Elsevier
Abstract The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the
Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer …
Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer …